for PCO formation is the proliferation of residual lens epithelial cells, which attach to and migrate along the lens surface.
The current standard therapy for after-cataract is photodisruption of the posterior capsule by Nd:YAG laser, which can be associated with significant complications. Alternative lens designs with sharp edges were not able to significantly reduce overall cataract surgical costs. The numerous pharmacological approaches to prevent posterior capsule opacification have not led to clinical success.
A novel non-toxic coating with alkylphosphocholines for ophthalmological implants significantly reduces proliferation of residual lens epithelial cells and the resulting posterior capsule opacification. The coated lens could be implanted in a standard cataract surgery setting without additional requirements.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
email@example.com | TechnologieAllianz e.V.
Peltier Adsorption Trap
29.11.2016 | TechnologieAllianz e.V.
Innovative method for producing analytical suspension cell lines
24.11.2016 | TechnologieAllianz e.V.
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy